One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

Autor: Camilla Andreasen, Jens J. Holst, Signe Foghsgaard, Louise Vedtofte, Lise Lotte Gluud, Jens Svare, Tina Vilsbøll, Jonatan I. Bagger, Tine D. Clausen, Charlotte Strandberg, Peter M Gørtz, Peter Damm, Emilie Bahne, Filip K. Knop, Henning Grønbæk, Elisabeth R. Mathiesen

Publikováno v: Vedtofte, L, Bahne, E, Foghsgaard, S, Bagger, J I, Andreasen, C, Strandberg, C, Gortz, P M, Holst, J J, Gronbaek, H, Svare, J A, Clausen, T D, Mathiesen, E R, Damm, P, Gluud, L L, Knop, F K & Vilsboll, T 2020, ' One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial ', Journal of Clinical Medicine, vol. 9, no. 10, 3213 . https://doi.org/10.3390/jcm9103213
Journal of Clinical Medicine, Vol 9, Iss 3213, p 3213 (2020)
Journal of Clinical Medicine
Volume 9
Issue 10
Vedtofte, L, Bahne, E, Foghsgaard, S, Bagger, J I, Andreasen, C, Strandberg, C, Gørtz, P M, Holst, J J, Grønbæk, H, Svare, J A, Clausen, T D, Mathiesen, E R, Damm, P, Gluud, L L, Knop, F K & Vilsbøll, T 2020, ' One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial ', Journal of Clinical Medicine, vol. 9, no. 10, 3213 . https://doi.org/10.3390/jcm9103213

Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc8ebb811d253f6ec0f6e168ca1c26a
https://curis.ku.dk/portal/da/publications/one-years-treatment-with-the-glucagonlike-peptide-1-receptor-agonist-liraglutide-decreases-hepatic-fat-content-in-women-with-nonalcoholic-fatty-liver-disease-and-prior-gestational-diabetes-mellitus-in-a-randomized-placebocontrolled-trial(803706d8-9787-420a-aa72-72318800a41d).html

[Metformin is a possible glucagon-like peptide 1 stimulator]

Autor: Emilie, Bahne, Andreas, Brønden, Tina, Vilsbøll, Filip Krag, Knop

Publikováno v: Ugeskrift for laeger. 180(12)

Metformin is an oral anti-hyperglycaemic drug used as first-line treatment of Type 2 diabetes. It is more effective when administered orally than when administered intravenously, and metformin formulations, which prolong the time residing in the gut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8cac760eb758aad8407f6e17cbfbb062
https://pubmed.ncbi.nlm.nih.gov/29559078

Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect

Autor: Elisabeth R. Mathiesen, Jens Svare, Peter Damm, Signe Foghsgaard, Tina Vilsbøll, Louise Vedtofte, Emilie S. Andersen, Filip K. Knop, Emilie Bahne, Tine D. Clausen, Jens J. Holst, Jonatan I. Bagger, Camilla Andreasen

Publikováno v: Diabetologia. 60(7)

We investigated whether a reduced incretin effect, as observed in patients with type 2 diabetes, can be detected in high-risk individuals, such as women with prior gestational diabetes mellitus (pGDM). In this cross-sectional study, 102 women without

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ca6672f69234f3a94f36d9ad80d6771
https://pubmed.ncbi.nlm.nih.gov/28364253

Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?

Autor: Signe Foghsgaard, Louise Vedtofte, Emilie Bahne, Camilla Andreasen, Liselotte Klint Christiansen, Jens Svare, Tine Dalsgaard Clausen, Elisabeth Reinhardt Mathiesen, Peter Damm, Lise Lotte Gluud, Knop, Filip K., Tina Vilsbøll

Publikováno v: Capital Region of Denmark

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::65200cabde0c0ce27f86e1217ba441f7
https://research.regionh.dk/en/publications/is-doubleblinding-achievable-in-a-placebocontrolled-trial-with-the-glucagonlikepeptide1-receptor-agonist-liraglutide(570e3537-00e0-4d49-b7f5-173c37e4dedb).html